-
公开(公告)号：US20210145957A1
公开(公告)日：2021-05-20
申请号：US17161119
申请日：2021-01-28
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US10829521B2
公开(公告)日：2020-11-10
申请号：US16713782
申请日：2019-12-13
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC: A61K39/095 , C07K14/22 , A61K39/00
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
公开(公告)号：US20200165582A1
公开(公告)日：2020-05-28
申请号：US16704744
申请日：2019-12-05
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20190112584A1
公开(公告)日：2019-04-18
申请号：US16104938
申请日：2018-08-19
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US09950058B2
公开(公告)日：2018-04-24
申请号：US15385611
申请日：2016-12-20
Applicant: Pfizer Inc.
Inventor： Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , C07K14/135 , C12N15/01 , C07K14/005 , C12N7/00 , A61K39/12 , A61K39/00
CPC classification number: A61K39/155 , A61K39/12 , A61K2039/575 , C07K14/005 , C07K2319/02 , C07K2319/21 , C07K2319/22 , C07K2319/40 , C07K2319/70 , C07K2319/735 , C12N7/00 , C12N2760/18522 , C12N2760/18534 , C12N2760/18571
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
Patent Agency Ranking
公开(公告)号：US11208633B2
公开(公告)日：2021-12-28
申请号：US16704744
申请日：2019-12-05
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US10946086B2
公开(公告)日：2021-03-16
申请号：US16245378
申请日：2019-01-11
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G. K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20210024589A1
公开(公告)日：2021-01-28
申请号：US17060067
申请日：2020-09-30
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC: C07K14/22 , A61K39/095
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
公开(公告)号：US20210023200A1
公开(公告)日：2021-01-28
申请号：US17060944
申请日：2020-10-01
Applicant: Pfizer Inc.
Inventor： Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , A61K39/12 , C07K14/005 , C12N7/00
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
30.发明申请公开(公告)号：US20200254081A1
公开(公告)日：2020-08-13
申请号：US16647124
申请日：2018-09-14
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Nicholas Randolph Everard Kitchin , Justin Keith Moran , Louise Pedneault , Michael W. Pride , Mark Edward Ruppen , Christopher Frederick Webber
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
-
-
-
-
-
-
-
-
Search Results
34
records
(took 0.029 seconds)
